With growing indications for chimeric antigen receptor (CAR) T-cell therapy, toxicity profiles
are evolving. There is an urgent and unmet need of approaches to optimally manage …

The clinical use of chimeric antigen receptor (CAR) T-cell therapy is growing rapidly
because of the expanding indications for standard-of-care treatment and the development of …

Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option
for people with previously refractory B cell malignancies and are under development for a …

Chimeric antigen receptor (CAR)-T cell therapy is an emerging staple in the treatment of
certain hematological malignancies. While CAR-T cells have produced robust responses in …

Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat
relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T …

The success of chimeric antigen receptor (CAR)-T cell therapy with impressive response
rates in hematologic malignancies but also promising data in solid tumors came along with …

Chimeric antigen receptor (CAR) T cell therapy is a novel therapy for patients with relapsed
or refractory hematologic malignancies. Most CAR T cell therapy recipients will experience …

Chimeric antigen receptor (CAR) T-cell therapy is one of the most innovative therapies for
haematological malignancies to emerge in a generation. Clinical studies have shown that a …

Introduction Chimeric antigen receptor (CAR) T-cell is among the most prevalent
approaches that act by directing T-cells toward cancer; however, they need to be optimized …

Chimeric antigen receptor (CAR) T-cell systemic immunotherapy has revolutionized how
clinicians treat several refractory and relapsed hematologic malignancies. Due to its peculiar …